Cycle Announces the Appointment of Angela Kurtz as Clinical Metabolic Director to lead its newly created Clinical Metaoblic Department

December 2nd 2020

Angela Kurtz

Boston, Mass. – 2 December 2020 – Cycle Pharmaceuticals (“Cycle”) is proud to announce the appointment of Ms. Angela Kurtz MS, RD, CDN as Clinical Metabolic Director.

Ms. Kurtz brings to Cycle more than 20 years’ clinical experience and joins Cycle from the Icahn School of Medicine at Mount Sinai (New York, US), where she served for the last 11 years as the Director of the Clinical Metabolic Nutrition Program.

Angela will lead the creation of a new service platform, providing scientific and clinical support for Cycle’s rare disease metabolic medicines – including nutritional informational expertise – improving overall patients’ engagement, educational support, enhanced adherence and compliance to treatments.

This will deepen and further improve the connection between Cycle and the wider healthcare provider community, patients and their families.

I am excited to be joining Cycle which I have watched with great interest over the past years. Cycle’s growth and development has been impressive due to its high-quality standards, and the passion, the competence and the dedication of its teams” said Angela Kurtz, the newly appointed Clinical Metabolic Director of Cycle. “I know that my extensive experience working with patients affected by inborn errors of metabolism and their multi-faceted support network will enable me to provide valuable input and care.”

 “Angela is one of the most experienced and highly regarded Registered Dieticians in the United States. I had the chance to see her work, and I’ve been always impressed by her capabilities and her devotion to patients. I am happy to bring these skills on board offering them to patients and clinicians creating a new service platform. The level of care and support that patients received under Angela’s direction at Mount Sinai will now be available 24/7 for all our metabolic patients and clinics in the US.” said Antonio Benedetti, CEO of Cycle.

About Cycle Pharmaceuticals
Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering best-in-class drug treatments and services to the under-served rare disease patient community. We focus on rare metabolic and neurological genetic conditions. Cycle is headquartered in Cambridge, UK and has offices in Boston, Mass. (USA). For more information, please visit and follow us on Twitter, LinkedIn, Facebook and Instagram.


Cycle Pharmaceuticals
Paula Bekinschtein,
Head of Global Marketing
Tel.: +44-1223-354118
GL-0050 (Date of preparation: December 2020)